SELLAS Life Sciences Group Inc. Stock News

- SELLAS In-licenses Worldwide Rights Outside of Greater China for Clinical-Stage Asset -

VANCOUVER, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) and its subsidiary Lowell Mineral Exploration Ecuador S.A. ("Solaris" or “the Compan

Sellas Life Sciences <> completed enrollment in a phase 1/2 trial of its lead asset galinpepimut-S ((GPS)) in combination with Mercks <> Keytruda (pembrolizumab) in second

Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis

SELLAS Life Sciences Group (SLS) announces that an IND application to initiate the first clinical trial in China for 3D189, also known as galinpepimut-S ((GPS)), has been accepted

Chinese Partner, 3D Medicines, Expects to Initiate Trial in Second Half of 2022 in Patients with Hematological Malignancies Who Achieved Objective Response After Receiving Standard Treatment Chinese P

VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce a significant new discovery

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing

SELLAS Life Sciences Group Inc (TSE:SLS)s stock price reached a new 52-week high during trading on Thursday after TD Securities raised their price target on the stock from C$21.00 to C$22.00. TD Securities currently has a speculative buy rating on the stock. SELLAS Life Sciences Group traded as high as C$15.21 and last traded at []

SELLAS Life Sciences Group Inc (TSE:SLS)s share price was up 0.5% during mid-day trading on Wednesday . The stock traded as high as C$14.24 and last traded at C$14.19. Approximately 361,992 shares changed hands during trading, an increase of 105% from the average daily volume of 176,645 shares. The stock had previously closed at C$14.12. []

The Common Cancer-associated Antigens (CAAs) Vaccine research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and

SELLAS Life Sciences Group (NASDAQ:SLS) had its price target reduced by Cantor Fitzgerald from $18.00 to $16.00 in a report issued on Friday, The Fly reports. They currently have an overweight rating on the stock. Several other research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of SELLAS Life Sciences Group []

Price T Rowe Associates Inc. MD lessened its holdings in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 42.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,500 shares of the companys stock after selling 11,600 shares during the []

Claims in Derivative Suits Related to Activities of SELLAS’ Predecessor, Galena Biopharma, Inc. Claims in Derivative Suits Related to Activities of SELLAS’ Predecessor, Galena Biopharma, Inc.

Claims in Derivative Suits Related to Activities of SELLAS Predecessor, Galena Biopharma, Inc. Claims in Derivative Suits Related to Activities of SELLAS Predecessor, Galena Biopharma, Inc.